StockWatch
·
Q1 FY-2027 RESULTS · MOLDTKPAC

Mold-Tek Q1: sales cross ₹300 Cr (+24.9% YoY) but PAT lags at +14% as D&A, finance costs bite

PAT +14.17% YoY · revenue +24.9% · margins compressing · inline vs street

Q1 FY27 resultsMOLDTKPACMold-Tek Packaging Limited27 Jul 2026 · 3 min read
Revenue

₹300.45 Cr

+24.9% YoY

PAT (standalone)

₹25.57 Cr

+14.17% YoY

Net margin

8.49%

-0.8pp YoY

EPS

₹7.7

Mold-Tek Packaging opened FY27 with revenue of ₹300.45 Cr, up 24.9% YoY (₹240.56 Cr) and 26.3% sequentially, crossing the ₹300 Cr quarterly mark for the first time on 6.25% YoY volume growth to 12,089 MT and firm realisations. Reported PAT rose 14.2% YoY to ₹25.57 Cr (₹22.40 Cr), or ~18-19% on an adjusted basis once the ₹0.82 Cr exceptional gain that inflated the year-ago base is stripped out. The clear tension in the print is that profit growth trailed topline: net margin slipped to 8.5% from 9.3% a year ago, even as the operating story stayed strong — EBITDA rose 19.1% YoY to ₹56.43 Cr and EBITDA/kg hit a historical high of ₹46.68 (vs ₹41.64 in Q1 FY26), well above the ₹42.5-43 management guided for FY27.

The scoreboard

Q1 FY-2027 vs prior quarters

Standalone P&L, ₹ Crore
Q1 FY-2027QoQYoY
Revenue₹300.45 Cr+26.3%+24.9%
Expenses₹266.86 Cr+26.9%+25.9%
PAT₹25.57 Cr+23.89%+14.17%
Net margin8.49%-0.2pp-0.8pp
EPS₹7.7+24%+14.2%

The margin bridge sits below the operating line: depreciation climbed 17.9% YoY to ₹16.55 Cr and finance costs jumped ~37.7% to ₹5.72 Cr, both flowing from the recent capex and the consolidation of five Hyderabad units into two (Annaram and Sultanpur), which lifted capacity utilisation to ~75% and brought printing under one roof. Management frames this as the driver of the record EBITDA/kg and expects the positive momentum to hold, led by Pharma Packs (+38.75% volume, a new high-margin vertical now adding clients and eyeing ophthalmic/medical-device packs), Food & FMCG (+26.2%, with eight new moulding machines commissioned at Sultanpur and Panipat output doubled) and Paints (+10.82%); Lube packs dipped on Iran-war-related client input issues.

536.83589.59642.35695.11747.87713.5504-2305-1506-0907-0207-2407-27Q1 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹713.55, up 3.5% over the past month of trading.

₹ Cr
09.5519.0928.6416.27Q4 FY25rev ₹203 Cr22.4Q1 FY26rev ₹241 Cr15.48Q2 FY26rev ₹210 Cr14.35Q3 FY26rev ₹198 Cr20.64Q4 FY26rev ₹238 Cr25.57Q1 FY27rev ₹300 Cr
Quarterly standalone PAT, ₹ Crore

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.

What management guided (4 FY-2026 call)
Management guides for a robust FY27 with 13-15% value growth, targeting over INR 1,000 crores in revenue, supported by 10-13% volume growth. Profitability is expected to see significant improvement, with EBITDA guided to grow approximately 20% to INR 210 crores and EBITDA per kg improving from INR 40.7 to a range of IN

This quarter: met

Against the FY27 guidance given on the May concall — 13-15% value growth toward >₹1,000 Cr revenue, ~20% EBITDA growth to ₹210 Cr, and EBITDA/kg of ₹42.5-43 — the quarter runs ahead on value growth and EBITDA/kg but light on volume: 6.25% YoY volume is below the 10-13% guided pace, the number to watch. Street context is full-year rather than quarterly (consensus ~₹927 Cr FY27 revenue / +23% EPS, +15-20% PAT); this print annualises ahead on topline but PAT growth is running a touch below that pace, consistent with the below-the-line drag. The board also declared results alongside a trading-window closure; a ₹2 interim dividend was declared in April.

  • W1

    Volume growth: 6.25% YoY vs the 10-13% FY27 guidance — needs to accelerate to hit the >₹1,000 Cr revenue and ₹210 Cr EBITDA targets

  • W2

    Net margin: whether rising depreciation/finance costs from capex keep compressing NPM (8.5% now vs 9.3% YoY) or EBITDA/kg gains (₹46.68) filter to the bottom line

  • W3

    Pharma ramp: sustaining ~38.75% volume growth plus the planned ophthalmic/medical-device and dosage-pen entries as the high-margin mix driver

Standalone only (one reportable segment; no consolidated). In ₹ lakh, converted to Cr. Current quarter has NIL exceptional item; year-ago Q1 FY26 PBT included a +₹0.82 Cr exceptional GAIN (PBT 30.01 vs 29.19 pre-exceptional), so raw YoY PAT understates underlying growth. Tax = current 7.99 - earlier-year 0.06 + deferred 0.67 = 8.60 Cr. All internal checks pass (301.03 total income; 34.17 PBT; 25.57 PAT).

Informational and educational content only. Not investment advice.